LivingGLP1
SGLT2 inhibitor

Canagliflozin

CANAGLIFLOZIN

Agent
canagliflozin
Dosing
fixed
Mechanism
Sodium glucose cotransporter 2 inhibitor
Trials
2
Participants in these arms
409

Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.

Related

    Effects across outcomes

    Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
    ConditionOutcomeWindowVersusEffect (95% CrI)SUCRA
    Type 2 diabetes (adults)HbA1c changeweeks 36 to 64 (target week 52)PlaceboMD 0.19 (-0.27 to 0.69)0.39
    Type 2 diabetes (adults)HbA1c changeweeks 36 to 64 (target week 52)PlaceboMD -0.22 (-1.47 to 1.15)0.47
    Type 2 diabetes (adults)HbA1c changeweeks 36 to 64 (target week 52)PlaceboMD -0.90 (-1.81 to 0.03)0.34
    Type 2 diabetes (adults)HbA1c changeweeks 36 to 64 (target week 52)PlaceboMD -1.07 (-2.34 to 0.47)0.47
    Type 2 diabetes (adults)HbA1c changeweeks 36 to 64 (target week 52)PlaceboMD 0.01 (-0.77 to 0.83)0.12
    Type 2 diabetes (adults)HbA1c changeweeks 36 to 64 (target week 52)PlaceboMD -0.27 (-1.09 to 0.62)0.22
    Type 2 diabetes (adults)Body weight change in kilograms (diabetes)weeks 36 to 64 (target week 52)PlaceboMD -2.46 (-5.01 to 0.68)0.66
    Type 2 diabetes (adults)Body weight change in kilograms (diabetes)weeks 36 to 64 (target week 52)PlaceboMD -3.38 (-8.86 to 2.58)0.74
    Type 2 diabetes (adults)HbA1c below 7 percentweeks 36 to 64 (target week 52)Semaglutide 1.0 mg subcutaneous once weeklyOR 0.33 (0.12 to 1.06)0.22
    Type 2 diabetes (adults)HbA1c below 7 percentweeks 36 to 64 (target week 52)Semaglutide injectionOR 0.33 (0.13 to 1.02)0.21
    Type 2 diabetes (adults)Level 2 or 3 hypoglycemia (participants)longest follow-upPlaceboHR 0.19 (0.02 to 1.15)0.90
    Type 2 diabetes (adults)Level 2 or 3 hypoglycemia (participants)longest follow-upPlaceboHR 0.50 (0.11 to 1.99)0.87
    Type 2 diabetes (adults)Systolic blood pressure changeweeks 36 to 64 (target week 52)PlaceboMD -0.21 (-6.22 to 5.71)0.78
    Type 2 diabetes (adults)Systolic blood pressure changeweeks 36 to 64 (target week 52)PlaceboMD -3.23 (-9.27 to 3.93)0.82
    Type 2 diabetes (adults)Weight loss of 5 percent or moreweeks 40 to 104 (target week 68)PlaceboOR 5.01 (0.66 to 17.46)0.68
    Type 2 diabetes (adults)Weight loss of 5 percent or moreweeks 40 to 104 (target week 68)PlaceboOR 6.37 (0.80 to 24.79)0.74
    Type 2 diabetes (adults)Weight loss of 10 percent or moreweeks 40 to 104 (target week 68)Semaglutide 1.0 mg subcutaneous once weeklyOR 0.34 (0.14 to 0.96)0.44
    Type 2 diabetes (adults)Weight loss of 10 percent or moreweeks 40 to 104 (target week 68)Semaglutide injectionOR 0.33 (0.13 to 0.90)0.47
    Type 2 diabetes (adults)SF-36 physical component summary changeweeks 20 to 130 (target week 52)PlaceboMD 1.69 (-0.43 to 4.00)0.78
    Type 2 diabetes (adults)SF-36 physical component summary changeweeks 20 to 130 (target week 52)PlaceboMD 1.34 (-2.08 to 4.97)0.74
    Type 2 diabetes (adults)Serious adverse eventslongest follow-upPlaceboHR 1.18 (0.61 to 2.33)0.40
    Type 2 diabetes (adults)Serious adverse eventslongest follow-upPlaceboHR 1.13 (0.57 to 2.30)0.41
    Type 2 diabetes (adults)Nausealongest follow-upPlaceboHR 0.79 (0.43 to 1.42)0.81
    Type 2 diabetes (adults)Nausealongest follow-upPlaceboHR 0.75 (0.34 to 1.60)0.66
    Type 2 diabetes (adults)Vomitinglongest follow-upPlaceboHR 0.51 (0.20 to 1.22)0.85
    Type 2 diabetes (adults)Vomitinglongest follow-upPlaceboHR 0.56 (0.18 to 1.62)0.78
    Type 2 diabetes (adults)Diarrhealongest follow-upPlaceboHR 1.16 (0.67 to 2.02)0.65
    Type 2 diabetes (adults)Diarrhealongest follow-upPlaceboHR 1.27 (0.68 to 2.43)0.53
    Type 2 diabetes (adults)Constipationlongest follow-upPlaceboHR 1.65 (0.81 to 3.31)0.50
    Type 2 diabetes (adults)Constipationlongest follow-upPlaceboHR 1.91 (0.93 to 3.83)0.37

    Trials